PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
Status:
Terminated
Trial end date:
2017-11-24
Target enrollment:
Participant gender:
Summary
The first part of this study is to find the recommended dosages of a combination of two
drugs: pazopanib and fosbretabulin, which will be given to female patients with relapsed
ovarian cancer.
The second part of the study involves comparing the recommended dose of pazopanib and
fosbretabulin in combination against pazopanib alone in female patients with relapsed ovarian
cancer to determine whether the combination is more beneficial that pazopanib on it's own.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Heather Driscoll The Christie NHS Foundation Trust
Collaborators:
East and North Hertfordshire NHS Trust Mateon Therapeutics Novartis